Merck Sharp Dome News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

United statesGeorgetown universityDistrict of columbiaMichael atkinsMichaelb atkinsUniversity of torontoGeorgetown lombardi comprehensive cancer centerDepartment of medical oncologyDatabase consortiumGeorgetown university medical centerMerck sharp domeSociety of urologic oncologyInternational metastaticAmerican society of clinical oncologyClinical oncologyAnnual meeting